• L-Alanyl-L-Glutamine (B8228): Lab Workflow Guide

  2026-08-08

  L-Alanyl-L-Glutamine (SKU B8228) provides a water-soluble dipeptide format for aqueous nutritional, gastrointestinal, and barrier-oriented workflows where matrix compatibility matters. This guide covers preparation and quality control from the product dossier; it should not be treated as evidence of clinical benefit or used in place of a DMSO- or ethanol-soluble reagent.

• Cy5 Goat Anti-Rabbit IgG: Assay Guide

  2026-08-07

  The Cy5 Goat Anti-Rabbit IgG (H+L) Antibody is a Cy5 conjugated secondary antibody for fluorescence detection of rabbit primary antibodies. Its affinity-purified polyclonal design supports immunofluorescence, immunohistochemistry, immunocytochemistry, western blotting, and flow cytometry, while the cited ASB3–MAVS study illustrates how this reagent class can support antiviral signaling research.

• Cy7 NHS Ester Protocols: Near-Infrared Dye for Bioimaging

  2026-08-07

  Cy7 NHS ester enables reliable, high-sensitivity labeling of proteins and peptides for near-infrared fluorescent imaging, particularly where water solubility and minimal sample perturbation are critical. This reagent is unsuitable for workflows requiring long-term storage of dye solutions or non-aqueous labeling environments. Adherence to best practices ensures reproducible results and prevents sample degradation.

• Epigenetic Modulation of Immune Signatures in Melanoma: Insi

  2026-08-06

  Anichini et al. provide a systematic comparative analysis of how diverse epigenetic inhibitors reshape immune-related gene expression in melanoma. The study identifies guadecitabine, a DNA methyltransferase inhibitor, as uniquely potent in activating innate immunity pathways, suggesting new avenues for combination immunotherapy.

• Foretinib (GSK1363089): Advanced Workflows for Tumor Inhibit

  2026-08-06

  Foretinib (GSK1363089) enables precise, multi-kinase targeting for dissecting tumor cell growth and metastasis in vitro and in vivo. This guide translates recent evidence and best practices into streamlined protocols, comparative advantages, and troubleshooting strategies for advanced cancer research.

• TCAIM Modulates Mitochondrial Metabolism via OGDH Regulation

  2026-08-05

  Wang et al. uncover that the mitochondrial DNAJC co-chaperone TCAIM specifically targets and reduces a-ketoglutarate dehydrogenase (OGDH) protein levels, revealing a novel post-translational regulatory mechanism for mitochondrial metabolism. This work advances our understanding of how proteostasis intersects with metabolic control and suggests new angles for interrogating energy homeostasis in cellular and disease models.

• Ridaforolimus (Deforolimus): Precision mTOR Targeting in Can

  2026-08-05

  Explore Ridaforolimus (Deforolimus) as a potent, selective mTOR inhibitor for advanced cancer research. This article offers a deep dive into mechanistic insights, practical protocol guidance, and the intersection of AI-driven senolytic discovery.

• Mechanistic Precision in qPCR: CXCL5, Obesity, and Translati

  2026-08-04

  This article dissects how advanced hot-start SYBR Green qPCR reagents, like APExBIO’s HotStart™ 2X Green qPCR Master Mix, are redefining quantitative gene expression analysis in the context of immuno-oncology and metabolic disease. By integrating mechanistic insights and recent breakthroughs on CXCL5-mediated immune modulation in pancreatic cancer, we offer translational researchers strategic guidance for building robust, clinically actionable workflows. The discussion advances beyond protocol-level recommendations, bridging molecular specificity with next-generation translational discovery.

• IGF2BP1-m6A-THBS1 Axis Drives Macrophage Fibrosis in the Lun

  2026-08-04

  This study reveals that IGF2BP1, an m6A RNA reader, promotes pulmonary fibrosis by stabilizing THBS1 mRNA in macrophages, thereby enhancing glycolytic metabolism and M2 polarization. These mechanistic insights highlight a novel IGF2BP1/THBS1/TLR4 axis as a promising target for modulating fibrosis and macrophage metabolic reprogramming.

• Tolazoline: Applied Workflows for α2-Adrenergic Antagonism

  2026-08-03

  Tolazoline stands out as a dual-action α2-adrenergic receptor antagonist and ATP-sensitive potassium channel blocker, enabling precise modulation in islet and airway models. This guide details optimized protocols, advanced troubleshooting, and translational insights for researchers seeking reproducibility and mechanistic clarity.

• Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) in Toxicolo

  2026-08-03

  Diuron is a benchmark photosynthesis inhibitor and nephrotoxicant, enabling advanced workflows in plant biology and environmental toxicology. This guide bridges mechanistic insight with practical protocol enhancements, troubleshooting, and best practices for Diuron-based assays.

• Angiotensin II in Vascular Remodeling: Protocols & Innovatio

  2026-08-02

  Harness Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) for reproducible modeling of hypertension and aortic aneurysm, driven by mechanistic insight into vascular smooth muscle cell dysfunction. This guide unpacks experimental workflows, troubleshooting, and the practical impact of mitochondrial NAD+ metabolism uncovered by recent multiomics research.

• Optimized hiPSC Platelet Production via Small Molecule Modul

  2026-08-01

  This study presents a systematically optimized protocol for deriving functional platelets from human induced pluripotent stem cells (hiPSCs), leveraging small molecule modulators to enhance yield and maturation. The findings provide a cost-effective, scalable approach with implications for transfusion medicine and cellular therapy.

• Roscovitine (Seliciclib): Applied CDK Inhibition in Cancer R

  2026-07-31

  Roscovitine (Seliciclib) empowers translational cancer research with unmatched selectivity for cyclin-dependent kinases, enabling precise cell cycle arrest and robust tumor growth inhibition in vivo. Discover optimized experimental workflows, troubleshooting strategies, and the impact of cheminformatics-guided library design on assay precision.

• VX-702: Advanced p38α MAPK Inhibitor for Inflammation Models

  2026-07-31

  VX-702 is redefining inflammation and cardiovascular research as a potent, selective p38α MAPK inhibitor, uniquely combining active site blockade with enhanced target dephosphorylation. This guide delivers actionable protocols, troubleshooting strategies, and advanced assay insights for maximizing data clarity and reproducibility in cytokine suppression and disease modeling.

458 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page